The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Open accessPublished version of a preprint
Abstract
BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Baricitinib, an inhibitor of JAK1 and JAK2, is reported to prevent COVID-19 severity followed by lowering IL-6 and TNFα levels (369).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [369]
Experimental — accuracy not yet measuredIn the citing paper
“In early clinical trials, the use of the JAK inhibitor baricitinib showed a reduction in serum levels of IL-6, IL-1β, and TNF (Bronte et al., 2020)”
From COVID-19 and the human innate immune system (2021) · cites this paper as Bronte et al., 2020
In the citing paper
“Further support comes from positive anecdotal reports of targeted antagonists against interleukin-1, granulocyte–macrophage colony-stimulating factor, and JAK1 and JAK2 in patients with Covid-19.102-105”
From Cytokine storm (2020) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Thevarajan, I., Nguyen, T. H. O., Koutsakos, M., Druce, J. D., Caly, L., van de Sandt, C. E., Jia, X., Nicholson, S. R., Catton, M. C., Cowie, B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0819-2 · Cited by 993
Cited by
Sorted by citations
Items 201–280 of 280
Li, J., Long, X., Zhang, Q., Fang, X., Luo, H., Fang, F., Lv, X., Zhang, D., Sun, Y., Li, N., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104415 · Cited by 3
Maria, N. I., Rapicavoli, R. V., Alaimo, S., Bischof, E. Y., Stasuzzo, A., Broek, J. A. C., Pulvirenti, A., Mishra, B., Duits, A. J., & Ferro, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14115 · Cited by 6
Völkel, S., Tarawneh, T. S., Sacher, L., Bhagwat, A. M., Karim, I., Mack, H. I. D., Wiesmann, T., Beutel, B., Hoyer, J. D., Keller, C. A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1176427 · Cited by 3
Tanaka, H., Chubachi, S., Namkoong, H., Sato, Y., Asakura, T., Lee, H., Azekawa, S., Otake, S., Nakagawara, K., Fukushima, T., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad311 · Cited by 3
Severe COVID-19 infection: An institutional review and literature overview
Akpoviroro, O., Sauers, N. K., Queeneth, U., Castagne, M., Akpoviroro, O. P., Humayun, S., Mirza, W., & Woodard, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304960 · Cited by 4
Luciani, G. R., Visigalli, R., Dall’Asta, V., Rotoli, B. M., & Barilli, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125916 · Cited by 3
Du, J., Li, X., Peng, X., Xu, W., Zhang, X., Li, H., Yang, T., Yuan, C., Chen, W., Li, C., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27854 · Cited by 3
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis
Niu, J., Lin, Z., He, Z., Yang, X.-J., Qin, L., Feng, S., Guan, L., Zhou, L., & Chen, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.973688 · Cited by 3
Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19
Koh, J., Ko, J., Lim, S. Y., Bae, S., Huh, K., Cho, S. Y., Kang, C., Chung, D. R., Chung, C. R., Kim, S., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109628 · Cited by 3
Tomos, I. P., Grigoropoulos, I., Kosti, C., Chrysikos, S., Digalaki, A., Thomas, Κ., Hillas, G., Kazakou, P., Antoniadou, A., Kavatha, D., et al. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2473486 · Cited by 2
Victorino, D. B., Malheiros, J. M., ten-Caten, F., Betta, V. H. C., Barbosa, F. F. S., Ghneim, K., Coirada, F. C., Bruno, F. R., de Medeiros, G. X., Silveira, C., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0338519 · Cited by 2
Bouzid, A., Elemam, N. M., AlSafar, H. S., Venkatachalam, T., Eldoahji, L., Halabi, N., Saleh, M. A., Talaat, I. M., Taneera, J., Sulaiman, N. D., et al. (2026) · Human Genomics · doi:10.1186/s40246-026-00928-9 · Cited by 2
Ikhar, R., Bele, H., Sabale, P., Warokar, A., & Sabale, V. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10498-x · Cited by 2
GateMeClass: Gate Mining and Classification of cytometry data
Caligola, S., Giacobazzi, L., Canè, S., Vella, A., Adamo, A., Ugel, S., Giugno, R., & Bronte, V. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae322 · Cited by 2
Self-citationA Glimpse for the subsistence from pandemic SARS-CoV-2 infection
Rath, S. K., Dash, A. K., Sarkar, N., & Panchpuri, M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107977 · Cited by 2
Development of an acute lung injury model for drug testing
Grunwell, J. R., Stephenson, S. T., Dallalio, G. A., Diani, B. A., Zaworski, C., Jordan, N., & Fitzpatrick, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-02078-9 · Cited by 2
Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review
Lorenz, D., & Pawliczak, R. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114394 · Cited by 2
Best Practices For Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19)
Elsaghir, H., & Adnan, G. (2021) · eCommons - AKU (Aga Khan University) · Cited by 2
JAK Inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19
Saeedi‐Boroujeni, A., & Asadi-Samani, M. (2022) · Current Drug Research Reviews · doi:10.2174/2589977514666220304203816 · Cited by 2
Titanji, B. K., Farley, M. M., Schinazi, R. F., & Marconi, V. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1210 · Cited by 2
Maria, N. I., Rapicavoli, R. V., Alaimo, S., Bischof, E. Y., Stasuzzo, A., Broek, J. A. C., Pulvirenti, A., Mishra, B., Duits, A. J., & Ferro, A. (2021) · Research Square · doi:10.21203/rs.3.rs-287183/v1 · Cited by 2
Lin, Z., Niu, J., Xu, Y., Qin, L., Ding, J., & Zhou, L. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3929406 · Cited by 2
CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy
Billmeier, A., Khinvasara, K., Lang, F., Mohr, J., Reidenbach, D., Schork, M., Yildiz, I., & Diken, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2024416 · Cited by 1
The development of therapeutics and vaccines against COVID-19.
Zhao, T., Wang, Z., Tong, M., & Fei, Y. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116643 · Cited by 1
Ugel, S., Gupta, A., Spiteri, G., Marchetti, P., Sanctis, F. D., Wouters, S., Konnova, A., Monaco, M. G. L., Carta, A., Pezzani, M. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1707449 · Cited by 1
Self-citationInfection at the vascular front: A delicate balance between defense and pathology
Zhou, J., Wang, D., & Yan, B. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.108261 · Cited by 1
Chang, E., Kim, M.-S., Park, Y. K., Kwon, K., Jang, H. M., Lim, S. Y., Bae, S., Jung, J., Kim, M. J., Chong, Y. P., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1734109 · Cited by 1
Li, C., Zhao, H., Cheng, L., & Wang, B. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s301173 · Cited by 1
Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19*
Cawcutt, K. A., & Kalil, A. C. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005757 · Cited by 1
Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia
Billi, A. C., Wasikowski, R., Ma, F., Yalavarthi, S., Hoy, C. K., Zuo, Y., Patrick, M. T., Shah, N., Parker, C., Aaronson, C., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166110 · Cited by 1
Baricitinib in the management of persistent actinic granuloma: An innovative therapeutic approach
An, R., Tang, J., Lei, H.-X., & Tu, Y. (2024) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_554_2024 · Cited by 1
Sharma, L., Singh, R., Ngeow, C., van der Geest, R., Duray, A. M., Tolman, N. J., McVerry, B. J., Cruz, C. S. D., Alcorn, J. F., Bain, W., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70232 · Cited by 1
Resist to persist: resistance of the HIV reservoir to immune-mediated clearance
Nguyen, T. D. T., Peligero-Cruz, C., & Mothe, B. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000975 · Cited by 2
Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19
Tandon, R., Paul, K., Tandon, N., & Luxami, V. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522999220128150814 · Cited by 1
Baricitinib as Treatment Option for Corona Virus Disease-19: a Literature Review
Handoyo, T., Farhanah, N., & Pamungkas, G. D. (2022) · Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal) · doi:10.14710/dmj.v11i5.35628 · Cited by 1
The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2
Syabbalo, N. (2022) · Journal of Lung Pulmonary & Respiratory Research · doi:10.15406/jlprr.2022.09.00273 · Cited by 2
Miller, A., & D'Silva, Y. A. (2021) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_80_21 · Cited by 1
Targeting COVID-19 Based on PathogenesisPreprint
Chong, Z. Z., & Zhang, H. (2024) · doi:10.22541/au.170665667.71444709/v1
Filho, W. A. D., de Paiva, C. M. M., Delgado, V. H. F., Lins, U. M. D. B. L., & França, E. D. S. (2021) · Saúde Coletiva (Barueri) · doi:10.36489/saudecoletiva.2021v11i64p5814-5821
Role of Steroids and Other Immunomodulators in Treatment of COVID-19
Rakshna, M., Arunkumar, A. S., & Mahadevan, L. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i47b33178
Estudo dos fármacos selecionados em ensaios clínicos na terapia farmacológica da COVID-19
Furuzawa, T. A., Cardia, G. F. E., Iwaki, M. V., Cremer, E., Spironello, R. A., Silva-Comar, F. M. D. S., & Cuman, R. K. N. (2022) · Research Society and Development · doi:10.33448/rsd-v11i1.24445
Inmunosupresión vs. Inmunorregulación en COVID-19
Durán-Méndez, A., Nieto-Ortega, E., & Peón, A. N. (2022) · PÄDI Boletín Científico de Ciencias Básicas e Ingenierías del ICBI · doi:10.29057/icbi.v9i18.8159
Bellone, M., Brevi, A., Bronte, V., Dusi, S., Ferrucci, P. F., Nisticò, P., Rosato, A., Russo, V. E. A., Sica, A., Toietta, G., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03145-0
Self-citationRocha, R. S., Costa, O. F. M. D., Veloso, R. C. D. S. G., & Bertollo, C. M. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n1-276
Hasan, M. J., Rabbani, R., Anam, A., & Huq, S. M. R. (2020) · doi:10.22541/au.159586089.96767674
Bergamo, A. B. H., Bitto, A., Grolla, A. A., Nocentini, G., Pierno, S., Pistis, M., Sava, G., & racagni, G. (2022) · doi:10.36118/pharmadvances.2022.37
Effectiveness and Safety of Baricitinib as a Covid-19 Drug Candidate: A Systematic Review
Rahayu, Y. S., Anggriani, A., Habibie, H., Wahyudin, E., & Bahar, M. A. (2022) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2022.11.1.78
Baricitinib in the Treatment of COVID-19
Atal, S., Sampath, A., Banerjee, A., & Jhaj, R. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107269
Immune-Targeted Therapies for COVID-19
Bartoletti, M., & Pascale, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_24
Huq, S. M. R., Ahmed, R., Ahmed, M., Rabbani, R., Hasan, J., & Anam, A. M. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3076
Cardiovascular implications of the COVID-19
Hamidian, M., Ansari, R., Zarshenas, M. M., & Foroughinia, F. (2022) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_895_21
Sun, J., Wang, S., Ma, X., Wei, Q., Yujuan, P., Bai, Y., Miao, G., Meng, C., & Liu, P. (2023) · doi:10.37766/inplasy2023.1.0086
Hirasawa, Y., Terada, J., Shionoya, Y., Fujikawa, A., Isaka, Y., Takeshita, Y., Kinouchi, T., Koshikawa, K., Tajima, H., Kinoshita, T., et al. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.03.009
Poliseno, M., Lacedonia, D., Niglio, M., Gregorio, F. D., Minafra, G. A., Campanino, T., Giganti, G., Scioscia, G., Santantonio, T. A., Barbaro, M. P. F., et al. (2023) · BioMed · doi:10.3390/biomed3020021
Mucus hypersecretion in COVID-19 patients: signaling pathway and related targeted therapies
SiYi, T. A. O., Juan, Y. U. E., Zhong, X. Y., Li, S., & Xia, Z. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2022-0251
Managing IBD in the COVID-19 era
Scalzo, N., & Ungaro, R. C. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231176450
Song, X., Xiao, X., Liu, L., Wei, X., & Li, F. (2023) · Signa Vitae · doi:10.22514/sv.2023.083
CHITV: an updated combination treatment regimen for COVID-19
Yan, Y., Hao, Y., Ling, Y., & Lu, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00087-3
COVID-19 – Fisiopatologia e intervenções farmacológicas: corticoides, Baricitinibe e Sotrovimabe
Veludo, A. C. D. C., Karam, J., Karam, L., & Pace, M. A. L. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-204
Selective epigenetic regulation of IFN-γ signature genes by JAK inhibitor in inflammatory diseasesPreprint
Kwon, G., Park, Y., Kang, K., & Kang, K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.05.606293
Improvement in Long COVID Symptoms in Two Individuals Treated with Baricitinib
Lladós, G., Marconi, V. C., Ely, E. W., Peluso, M. J., Gavegnano, C., Hsue0, P. Y., López, C., Loste, C., Santos, J. R., Casafont, I., et al. (2024) · Annals of Case Reports · doi:10.29011/2574-7754.101939
The Role of Ursodeoxycholic Acid Administration During the COVID‐19 Pandemic: A Questionnaire Survey
Zhou, C., Jia, R., Yang, J. S. W., Liu, T., Liu, X., Yang, L., & Zhao, W. (2025) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/cjid/4601882
Viola, H., Chen, L.-H., Jo, S., Washington, K., Selva, C., Li, A., Feng, D., Giacalone, V. D., Stephenson, S. T., Cottrill, K. A., et al. (2025) · APL Bioengineering · doi:10.1063/5.0220367 · Cited by 1
Insights into potential therapeutic approaches for long COVID
Zhao, J., Lyu, Y., & Qu, J. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1149-z
Functional immune changes are conserved in COVID-19 and trauma patients receiving intensive care
Wood, A. J. T., Albers, G. J., Cornelissen, W., Maiden, J. D., Cuff, D. E., Ashayeripanah, M., Schriek, P., Emery‐Corbin, S. J., Scott, N. E., Li, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75748-5
Nian, Z., Mao, Y., Xu, Z., Deng, M., Xu, Y., Xu, H., Chen, R., Xu, Y., Huang, N., Mao, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26019562
Ciccocioppo, R., Gibellini, D., Astori, G., Bernardi, M., Bozza, A., Chieregato, K., Elice, F., Ugel, S., Caligola, S., Sanctis, F. D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14721962
Self-citationSun, J., Wang, S., Ma, X., Wei, Q., Peng, Y., Bai, Y., Miao, G., Meng, C., & Liu, P. (2024) · Figshare · doi:10.6084/m9.figshare.24603996
Sun, J., Wang, S., Ma, X., Wei, Q., Peng, Y., Bai, Y., Miao, G., Meng, C., & Liu, P. (2023) · Figshare · doi:10.6084/m9.figshare.24603585
Liu, Z., Huang, L., Yu, J., Yu, Q. C., Liu, M., Gao, Y., Qin, X., Lai, J., Ling, F., Chang, Y., et al. (2026) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2026.111205
Siddheshwar, S. S., Bairagi, S., Mankar, S. D., & Ghorpade, A. C. (2026) · INDIAN DRUGS · doi:10.53879/id.63.02.15629
ERS Congress 2025: highlights from the Respiratory Intensive Care Assembly
Jiménez-Gómez, M., Leo, G. D., João, M., Lam, L.-P., Padilla, D. E. L., Machado, T. M. S. C., Pais, M., Stamatopoulou, V., Vilde, R., Fisser, C., et al. (2026) · ERJ Open Research · doi:10.1183/23120541.01733-2025
杜, 连. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631153
Gelles, K., Kurz, V., Butylina, M., Wahl‐Figlash, K., Schepelmann, M., Meshcheryakova, A., & Pietschmann, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115047
The use of JAK inhibitors and tocilizumab in the management of TRAPS: a sibling case study
Thai, D., Tiller, G., Akikusa, J. D., Taranto, M., Shepherd, K., Masters, S. L., & Mehr, S. S. (2026) · Pediatric Rheumatology · doi:10.1186/s12969-026-01225-4
Rush, M. N. M., Hoofnagle, M. H., Niziolek, G. M., Ghosh, S., Spinella, P. C., Bochicchio, G. V., & Turnbull, I. R. (2026) · Shock · doi:10.1097/shk.0000000000002881
Avci, A., Taşci, H., Sağlık, B. N., Tozkoparan, B., & Kelekçi, N. G. (2026) · ACS Omega · doi:10.1021/acsomega.6c02611
Ghazy, F. H., El-Bagary, R. I., Fahim, S. H., & Mahmoud, S. T. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2715920
Lyu, X., Wang, Y., Yang, J., Zhang, Y., Min, W., & Du, N. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1752145
BindingDB (2026) · UC San Diego · doi:10.7270/q2p2742q
Metadata
- Authors
- Bronte, V., Ugel, S., Tinazzi, E., Vella, A., De Sanctis, F., Canè, S., Batani, V., Trovato, R., Fiore, A., Petrova, V., Hofer, F., Barouni, R. M., Musiu, C., Caligola, S., Pinton, L., Torroni, L., Polati, E., Donadello, K., Friso, S., Pizzolo, F., Iezzi, M., Facciotti, F., Pelicci, P. G., Righetti, D., Bazzoni, P., Rampudda, M., Comel, A., Mosaner, W., Lunardi, C., & Olivieri, O.
- Affiliations
- University of Verona (IT)
- European Institute of Oncology (IT)
- Ospedale P. Pederzoli – Casa di Cura Privata S.p.a. (IT)
- Corresponding author
- Bronte, Vincenzo
- ORCID
- Bronte, Vincenzo
- Ugel, Stefano
- Tinazzi, Elisa
- Vella, Antonio
- Canè, Stefania
- Batani, Veronica
- Trovato, Rosalinda
- Fiore, Alessandra
- Petrova, Varvara
- Hofer, Francesca
- Barouni, Roza Maria
- Musiu, Chiara
- Caligola, Simone
- Pinton, Laura
- Torroni, Lorena
- Polati, Enrico
- Donadello, Katia
- Friso, Simonetta
- Pizzolo, Francesca
- Iezzi, Manuela
- Facciotti, Federica
- Pelicci, Pier Giuseppe
- Lunardi, Claudio
- Olivieri, Oliviero
- Venue
- Journal of Clinical Investigation
- Published
- 2020-11-03
- Volume
- 130
- Issue
- 12
- Pages
- 6409-6416
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC8016181
- OpenAlex
- W3037867966
- Cited by
- 281
- References
- 23
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 23 · 2023: 39 · 2022: 72 · 2021: 89 · 2020: 23
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Fondazione Cariverona Italy (ENACT)
- Fondazione TIM Italy (IMMUNOVID)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- baricitinib, COVID-19 pandemic, SARS-CoV-2, JAK/STAT signaling, STAT3 phosphorylation, cytokine storm, interleukin-6, IL-1β, TNF-α, lymphopenia, T cell reconstitution, B cell recovery, SARS-CoV-2 antibodies
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Aged, Aged, 80 and over, Azetidines, B-Lymphocytes, Female, Humans, Longitudinal Studies, Male, Middle Aged, Purines, Pyrazoles, Severity of Illness Index, Sulfonamides, T-Lymphocytes, Cytokines, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
